Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
2.780
-0.020 (-0.71%)
At close: Dec 20, 2024, 4:00 PM
2.630
-0.150 (-5.40%)
After-hours: Dec 20, 2024, 7:20 PM EST
Sunshine Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 32.96 | 24.09 | 4.35 | 0.23 | 0.07 | 0.02 | Upgrade
|
| Revenue Growth (YoY) | 61.94% | 454.42% | 1802.41% | 219.88% | 238.10% | - | Upgrade
|
| Cost of Revenue | 22.81 | 15.75 | 2.65 | 0.12 | 0.03 | 0.01 | Upgrade
|
| Gross Profit | 10.14 | 8.34 | 1.7 | 0.11 | 0.05 | 0.01 | Upgrade
|
| Selling, General & Admin | 12.95 | 10.83 | 9.48 | 1.87 | 0.61 | 0.62 | Upgrade
|
| Research & Development | 1.6 | 1.86 | 0.81 | 0.67 | 0 | 0.02 | Upgrade
|
| Other Operating Expenses | 0.35 | 0.29 | 0.06 | - | - | - | Upgrade
|
| Operating Expenses | 15.11 | 13.12 | 10.37 | 2.55 | 0.62 | 0.65 | Upgrade
|
| Operating Income | -4.96 | -4.79 | -8.67 | -2.44 | -0.58 | -0.64 | Upgrade
|
| Interest Expense | -0.03 | -0.14 | -0.04 | -0.33 | -0.17 | -0.12 | Upgrade
|
| Interest & Investment Income | 0.58 | 0.81 | 0.52 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.3 | -0 | -0 | 0 | 0 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -4.11 | -4.11 | -8.2 | -2.77 | -0.74 | -0.77 | Upgrade
|
| Impairment of Goodwill | - | - | -18.33 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.01 | -9.67 | -2.05 | -0.31 | Upgrade
|
| Pretax Income | -4.11 | -4.11 | -26.51 | -12.44 | -2.78 | -1.08 | Upgrade
|
| Income Tax Expense | 0.11 | 0.4 | 0.23 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -4.23 | -4.51 | -26.74 | -12.44 | -2.78 | -1.08 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -0.58 | Upgrade
|
| Net Income | -4.23 | -4.51 | -26.74 | -12.44 | -2.78 | -1.66 | Upgrade
|
| Net Income to Common | -4.23 | -4.51 | -26.74 | -12.44 | -2.78 | -1.66 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | - | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - | Upgrade
|
| EPS (Basic) | -25.31 | -370.38 | - | - | - | - | Upgrade
|
| EPS (Diluted) | -26.01 | -380.00 | - | - | - | - | Upgrade
|
| Free Cash Flow | -12.99 | -8.86 | -5.44 | -1.83 | -0.66 | -0.5 | Upgrade
|
| Free Cash Flow Per Share | -77.78 | -728.04 | - | - | - | - | Upgrade
|
| Gross Margin | 30.78% | 34.61% | 39.04% | 48.42% | 63.80% | 47.68% | Upgrade
|
| Operating Margin | -15.05% | -19.86% | -199.60% | -1068.24% | -807.83% | -3037.91% | Upgrade
|
| Profit Margin | -12.82% | -18.70% | -615.44% | -5444.41% | -3898.74% | -7860.85% | Upgrade
|
| Free Cash Flow Margin | -39.40% | -36.76% | -125.24% | -800.75% | -922.13% | -2351.49% | Upgrade
|
| EBITDA | -4.76 | -4.64 | -8.65 | -2.43 | -0.56 | -0.63 | Upgrade
|
| EBITDA Margin | -14.45% | -19.24% | -199.03% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.2 | 0.15 | 0.03 | 0.01 | 0.01 | 0.01 | Upgrade
|
| EBIT | -4.96 | -4.79 | -8.67 | -2.44 | -0.58 | -0.64 | Upgrade
|
| EBIT Margin | -15.05% | -19.86% | -199.60% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.